142 related articles for article (PubMed ID: 38385290)
21. Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study.
Foss-Freitas MC; Akinci B; Neidert A; Bartlett VJ; Hurh E; Karwatowska-Prokopczuk E; Oral EA
Lipids Health Dis; 2021 Dec; 20(1):174. PubMed ID: 34865644
[TBL] [Abstract][Full Text] [Related]
22. Pre-operative levels of angiopoietin protein-like 3 (ANGPTL3) in women diagnosed with high-grade serous carcinoma of the ovary.
Wong Chong E; Joncas FH; Douville P; Bachvarov D; Diorio C; Calon F; Bergeron AC; Blais J; Leung SOA; Seidah NG; Gangloff A
Lipids Health Dis; 2024 Feb; 23(1):59. PubMed ID: 38414008
[TBL] [Abstract][Full Text] [Related]
23. Hepatic Inhibition of ANGPTL3 Mimics the Molecular Hallmarks of Hypothyroidism.
Taebnia N; Lauschke VM
Arterioscler Thromb Vasc Biol; 2024 May; 44(5):1098-1100. PubMed ID: 38450511
[No Abstract] [Full Text] [Related]
24. Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion.
Wang Y; Gusarova V; Banfi S; Gromada J; Cohen JC; Hobbs HH
J Lipid Res; 2015 Jul; 56(7):1296-307. PubMed ID: 25954050
[TBL] [Abstract][Full Text] [Related]
25. Angiopoietin-like proteins and postprandial partitioning of fatty acids.
DiDonna NM; Chen YQ; Konrad RJ
Curr Opin Lipidol; 2022 Feb; 33(1):39-46. PubMed ID: 34789669
[TBL] [Abstract][Full Text] [Related]
26. Angiopoietin-like 3 regulates hepatocyte proliferation and lipid metabolism in zebrafish.
Lee SH; So JH; Kim HT; Choi JH; Lee MS; Choi SY; Kim CH; Kim MJ
Biochem Biophys Res Commun; 2014 Apr; 446(4):1237-42. PubMed ID: 24685482
[TBL] [Abstract][Full Text] [Related]
27. Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia.
Chen PY; Gao WY; Liou JW; Lin CY; Wu MJ; Yen JH
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34298929
[TBL] [Abstract][Full Text] [Related]
28. Genetic Mimicry Analysis Reveals the Specific Lipases Targeted by the ANGPTL3-ANGPTL8 Complex and ANGPTL4.
Landfors F; Chorell E; Kersten S
J Lipid Res; 2023 Jan; 64(1):100313. PubMed ID: 36372100
[TBL] [Abstract][Full Text] [Related]
29. Differential association of plasma angiopoietin-like proteins 3 and 4 with lipid and metabolic traits.
Mehta N; Qamar A; Qu L; Qasim AN; Mehta NN; Reilly MP; Rader DJ
Arterioscler Thromb Vasc Biol; 2014 May; 34(5):1057-63. PubMed ID: 24626437
[TBL] [Abstract][Full Text] [Related]
30. Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency.
Arca M; D'Erasmo L; Minicocci I
Curr Opin Lipidol; 2020 Apr; 31(2):41-48. PubMed ID: 32022755
[TBL] [Abstract][Full Text] [Related]
31. Metabolic profiling of angiopoietin-like protein 3 and 4 inhibition: a drug-target Mendelian randomization analysis.
Wang Q; Oliver-Williams C; Raitakari OT; Viikari J; Lehtimäki T; Kähönen M; Järvelin MR; Salomaa V; Perola M; Danesh J; Kettunen J; Butterworth AS; Holmes MV; Ala-Korpela M
Eur Heart J; 2021 Mar; 42(12):1160-1169. PubMed ID: 33351885
[TBL] [Abstract][Full Text] [Related]
32. Post-GWAS methodologies for localisation of functional non-coding variants: ANGPTL3.
Oldoni F; Palmen J; Giambartolomei C; Howard P; Drenos F; Plagnol V; Humphries SE; Talmud PJ; Smith AJ
Atherosclerosis; 2016 Mar; 246():193-201. PubMed ID: 26800306
[TBL] [Abstract][Full Text] [Related]
33. Hepatic ER stress suppresses adipose browning through ATF4-CIRP-ANGPTL3 cascade.
Lv S; Zhou Y; Chen J; Yuan H; Zhang ZN; Luan B
Cell Rep; 2022 Sep; 40(13):111422. PubMed ID: 36170814
[TBL] [Abstract][Full Text] [Related]
34. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia.
Gaudet D; Karwatowska-Prokopczuk E; Baum SJ; Hurh E; Kingsbury J; Bartlett VJ; Figueroa AL; Piscitelli P; Singleton W; Witztum JL; Geary RS; Tsimikas S; O'Dea LSL;
Eur Heart J; 2020 Oct; 41(40):3936-3945. PubMed ID: 32860031
[TBL] [Abstract][Full Text] [Related]
35. Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8.
Sylvers-Davie KL; Davies BSJ
Am J Physiol Endocrinol Metab; 2021 Oct; 321(4):E493-E508. PubMed ID: 34338039
[TBL] [Abstract][Full Text] [Related]
36. Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3).
Ginsberg HN; Goldberg IJ
Arterioscler Thromb Vasc Biol; 2023 Mar; 43(3):388-398. PubMed ID: 36579649
[TBL] [Abstract][Full Text] [Related]
37. The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Reeskamp LF; Tromp TR; Stroes ESG
Curr Opin Lipidol; 2020 Jun; 31(3):140-146. PubMed ID: 32324598
[TBL] [Abstract][Full Text] [Related]
38. Reduced miR-181d level in obesity and its role in lipid metabolism via regulation of ANGPTL3.
Abu-Farha M; Cherian P; Al-Khairi I; Nizam R; Alkandari A; Arefanian H; Tuomilehto J; Al-Mulla F; Abubaker J
Sci Rep; 2019 Aug; 9(1):11866. PubMed ID: 31413305
[TBL] [Abstract][Full Text] [Related]
39. ANGPTL3 as therapeutic target.
Kersten S
Curr Opin Lipidol; 2021 Dec; 32(6):335-341. PubMed ID: 34581310
[TBL] [Abstract][Full Text] [Related]
40. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease.
Dewey FE; Gusarova V; Dunbar RL; O'Dushlaine C; Schurmann C; Gottesman O; McCarthy S; Van Hout CV; Bruse S; Dansky HM; Leader JB; Murray MF; Ritchie MD; Kirchner HL; Habegger L; Lopez A; Penn J; Zhao A; Shao W; Stahl N; Murphy AJ; Hamon S; Bouzelmat A; Zhang R; Shumel B; Pordy R; Gipe D; Herman GA; Sheu WHH; Lee IT; Liang KW; Guo X; Rotter JI; Chen YI; Kraus WE; Shah SH; Damrauer S; Small A; Rader DJ; Wulff AB; Nordestgaard BG; Tybjærg-Hansen A; van den Hoek AM; Princen HMG; Ledbetter DH; Carey DJ; Overton JD; Reid JG; Sasiela WJ; Banerjee P; Shuldiner AR; Borecki IB; Teslovich TM; Yancopoulos GD; Mellis SJ; Gromada J; Baras A
N Engl J Med; 2017 Jul; 377(3):211-221. PubMed ID: 28538136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
